|Other Names||Deoxynucleotidyltransferase terminal-interacting protein 1, Terminal deoxynucleotidyltransferase-interacting factor 1, TdIF1, TdT-interacting factor 1, DNTTIP1, C20orf167, TDIF1|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP13202c was selected from the Center region of DNTTIP1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Increases DNTT terminal deoxynucleotidyltransferase activity (in vitro) (PubMed:11473582). Also acts as a transcriptional regulator, binding to the consensus sequence 5'- GNTGCATG-3' following an AT-tract. Associates with RAB20 promoter and positively regulates its transcription. Binds DNA and nucleosomes; may recruit HDAC1 complexes to nucleosomes or naked DNA.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
DNTTIP1 binds DNA and enhances the activity of terminaldeoxynucleotidyltransferase (TDT, or DNTT; MIM 187410), a DNApolymerase that catalyzes the polymerization of DNA in the absenceof a DNA template (Yamashita et al., 2001 [PubMed11473582]).
Kubota, T., et al. Genes Cells 12(8):941-959(2007)Lamesch, P., et al. Genomics 89(3):307-315(2007)Olsen, J.V., et al. Cell 127(3):635-648(2006)Olsen, J.V., et al. Cell 127(3):635-648(2006)Tomarev, S.I., et al. Invest. Ophthalmol. Vis. Sci. 44(6):2588-2596(2003)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.